Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan
Rivastigmine has been widely used in mild-to-moderate Alzheimer's disease (AD), but the therapeutic response rate varies from 20 to 60%. A dose-dependent effect has been suggested, but the plasma concentration of rivastigmine and its metabolite, NAP 226-90, were not measured in previous studies. The...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2017-06-01
|
| Серія: | Kaohsiung Journal of Medical Sciences |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S1607551X16302649 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|